{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T05:16:53Z","timestamp":1788239813368,"version":"build-2803163510"},"reference-count":18,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is an aggressive hematologic malignancy originating from plasmacytoid dendritic cell precursors. While classic cases present with prominent cutaneous nodules and lymphadenopathy, predominant generalized lymphadenopathy can obscure the diagnosis, frequently resulting in a misdiagnosis of systemic lymphoma.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case presentation<\/jats:title>\n                    <jats:p>A 56-year-old male presented with a one-month history of generalized pruritic erythema and multi-regional lymphadenopathy. Initial PET-CT demonstrated systemic lymphadenopathy and splenomegaly with increased metabolic activity, mimicking lymphoma. To establish a definitive diagnosis, integrated biopsies of the skin, bone marrow, and inguinal lymph nodes were performed. Bone marrow cytology revealed that unidentified cells accounted for 7% of the total nucleated cells. Immunohistochemical analysis revealed neoplastic cells positive for CD123, CD4, CD56, TCF4, and TCL1, confirming the diagnosis of BPDCN. The patient achieved complete remission (CR) after two cycles of induction chemotherapy with the DA (daunorubicin and cytarabine) regimen, followed by successful consolidation via allogeneic hematopoietic stem cell transplantation (allo-HSCT). At the 4-month post-transplant follow-up, the patient remains in stable remission with no evidence of disease recurrence.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This report details a BPDCN presentation that closely mimics systemic lymphoma. A definitive diagnosis hinges on the integration of multi-site histopathological analysis and comprehensive radiographic findings. Early diagnostic precision is paramount for the timely initiation of intensified therapeutic strategies, such as allo-HSCT, which remain the cornerstone for improving long-term survival in this recalcitrant malignancy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fmed.2026.1934512","type":"journal-article","created":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T04:26:31Z","timestamp":1788236791000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Case Report: Blastic plasmacytoid dendritic cell neoplasm mimicking systemic lymphoma: a multidisciplinary diagnostic challenge"],"prefix":"10.3389","volume":"13","author":[{"given":"Baixue","family":"Lv","sequence":"first","affiliation":[{"name":"Department of Oncology, Xiangyang No. 1 People\u2019s Hospital, Hubei University of Medicine","place":["Xiangyang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qin","family":"Rong","sequence":"additional","affiliation":[{"name":"Department of Pathology, Xiangyang No. 1 People\u2019s Hospital, Hubei University of Medicine","place":["Xiangyang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Pulmonary and Critical Care Medicine, Xiangyang Central Hospital, Hubei University of Arts and Science","place":["Xiangyang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongdong","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Oncology, Xiangyang Central Hospital, Hubei University of Arts and Science","place":["Xiangyang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,1]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1002\/ajh.2830470406","article-title":"High expression of CD56 (N-CAM) in a patient with cutaneous CD4-positive lymphoma","volume":"47","author":"Adachi","year":"1994","journal-title":"Am J Hematol"},{"key":"B2","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1002\/1097-0142(19950515)75:10<2474::AID-CNCR2820751013>3.0.CO;2-Y","article-title":"Acute agranular CD4-positive natural killer cell leukemia. Comprehensive clinicopathologic studies including virologic and in vitro culture with inducing agents","volume":"75","author":"Brody","year":"1995","journal-title":"Cancer"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","article-title":"The 5th edition of the world health organization classification of haematolymphoid tumours: myeloid and histiocytic\/dendritic neoplasms","volume":"36","author":"Khoury","year":"2022","journal-title":"Leukemia"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1002\/ajh.27737","article-title":"Blastic plasmacytoid dendritic cell neoplasm (BPDCN): 2025 update on diagnosis, pathophysiology, risk assessment, and management","volume":"100","author":"Shimony","year":"2025","journal-title":"Am J Hematol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.leukres.2018.08.014","article-title":"Epidemiology and survival of blastic plasmacytoid dendritic cell neoplasm","volume":"73","author":"Guru Murthy","year":"2018","journal-title":"Leuk Res"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.1056\/NEJMoa1815105","article-title":"Tagraxofusp in blastic plasmacytoid dendritic-cell neoplasm","volume":"380","author":"Pemmaraju","year":"2019","journal-title":"N Engl J Med"},{"key":"B7","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1038\/nri3865","article-title":"The multifaceted biology of plasmacytoid dendritic cells","volume":"15","author":"Swiecki","year":"2015","journal-title":"Nat Rev Immunol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1182\/blood.2019001144","article-title":"Multicenter analysis of outcomes in blastic plasmacytoid dendritic cell neoplasm offers a pretargeted therapy benchmark","volume":"134","author":"Taylor","year":"2019","journal-title":"Blood"},{"key":"B9","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1111\/bjd.12412","article-title":"Blastic plasmacytoid dendritic cell neoplasm: clinical features in 90 patients","volume":"169","author":"Julia","year":"2013","journal-title":"Br J Dermatol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"3027","DOI":"10.1182\/bloodadvances.2021006645","article-title":"Characteristics and outcomes of patients with blastic plasmacytoid dendritic cell neoplasm treated with frontline HCVAD","volume":"6","author":"Pemmaraju","year":"2022","journal-title":"Blood Adv"},{"key":"B11","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1080\/17512433.2019.1662297","article-title":"Tagraxofusp, the first CD123-targeted therapy and first targeted treatment for blastic plasmacytoid dendritic cell neoplasm","volume":"12","author":"Economides","year":"2019","journal-title":"Expert Rev Clin Pharmacol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"4121","DOI":"10.1007\/s00277-025-06493-w","article-title":"Durable outcomes with manageable safety leading to prolonged survival with tagraxofusp for treatment-naive patients with blastic plasmacytoid dendritic cell neoplasm: real world results from a European named patient program","volume":"104","author":"Herling","year":"2025","journal-title":"Ann Hematol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1016\/j.clml.2018.07.295","article-title":"Allogeneic hematopoietic cell transplantation is an effective treatment for blastic plasmacytoid dendritic cell neoplasm in first complete remission: systematic review and meta-analysis","volume":"18","author":"Kharfan-Dabaja","year":"2018","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"B14","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1038\/s41409-021-01478-5","article-title":"Allogeneic hematopoietic cell transplantation for patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN)","volume":"57","author":"Bashir","year":"2022","journal-title":"Bone Marrow Transplant"},{"key":"B15","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1158\/2159-8290.CD-16-0999","article-title":"Blastic plasmacytoid dendritic cell neoplasm is dependent on BCL2 and sensitive to venetoclax","volume":"7","author":"Montero","year":"2017","journal-title":"Cancer Discov"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1425833","DOI":"10.3389\/fmed.2024.1425833","article-title":"Venetoclax combined with azacitidine in blastic plasmacytoid dendritic cell neoplasm: a case report and comprehensive review on the current and future treatment","volume":"11","author":"Wang","year":"2024","journal-title":"Front Med (Lausanne)"},{"key":"B17","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1182\/blood.2022017865","article-title":"North American blastic plasmacytoid dendritic cell neoplasm consortium: position on standards of care and areas of need","volume":"141","author":"Pemmaraju","year":"2023","journal-title":"Blood"},{"key":"B18","doi-asserted-by":"publisher","first-page":"2228","DOI":"10.1038\/s41467-022-29669-8","article-title":"Targeting CD123 in blastic plasmacytoid dendritic cell neoplasm using allogeneic anti-CD123 CAR T cells","volume":"13","author":"Cai","year":"2022","journal-title":"Nat Commun"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1934512\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T04:26:32Z","timestamp":1788236792000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1934512\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,1]]},"references-count":18,"alternative-id":["10.3389\/fmed.2026.1934512"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2026.1934512","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,1]]},"article-number":"1934512"}}